🇧🇪 ARGX.BR — argenx SE

Salud Compra fuerte
← Volver

Precio actual

815,60 EUR

Máx. histórico

912,40

63 días

Caída desde máximo

-10,61%

Rango 52 semanas

568,40 – 925,00

Variación hoy

+0,07%

Cierre anterior

815,00

Rango de hoy

812,40 – 835,80

Volumen hoy

109.168

Peor caída histórica

-39,26%

21/07/2023 → 21/12/2023

Recuperado en 262 días

Volatilidad anualizada ⓘ

43,77%

Información
Nombre completo
argenx SE
Divisa
EUR
Mercado
Brussels
Sector
Salud
Industria
Biotechnology
Empleados
1.863
PER ⓘ
32,82 (puede no estar actualizado)
Dividend yield
0,00% (puede no estar actualizado)
Precio objetivo analistas
998,93 EUR (puede no estar actualizado)
Primera cotización
10/07/2014
Precio actualizado
hace 22 horas
Sobre la empresa

argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally. The company offers VYVGART for the treatment of gMG and immune thrombocytopenia (ITP), and VYVGART HYTRULO for the treatment of gMG and chronic inflammatory demyelinating polyneuropathy (CIDP). It also develops efgartigimod for the treatment of seronegative gMG, ocular myasthenia gravis (MG), primary ITP, grave's disease, myositis, Sjögren's disease, systemic sclerosis, and AMR; empasiprubart for MMN, delayed graft function, and CIDP; and adimanebart for congenital myasthenic syndrome and spinal muscular atrophy. In addition, the company is developing ARGX-213, a neonatal Fc receptor (FcRn)-targeted antibody engineered for half-life extension and sustained IgG reduction; ARGX-124, a FcRn pipeline candidate; ARGX-109, which targets IL-6 to treat inflammation; ARGX-121, which targets immunoglobulin A; and ARGX-118, which develops antibodies against Galectin-10, as well as cusatuzumab, ARGX-112, ARGX-114, and ARGX-115. It has strategic partnerships and license agreements with Zai Lab to develop and commercialize efgartigimod; Halozyme Therapeutics to its ENHANZE for the prevention and treatment of human diseases; OncoVerity, Inc for cusatuzumab; and AbbVie, Inc. for ARGX-115. argenx SE was incorporated in 2008 and is based in Amsterdam, the Netherlands.

Rentabilidad mensual
Evolución
Histórico día a día
Fecha Apertura Máximo Mínimo Cierre Variación Volatilidad día Volumen
12/06/2023 365,60 370,40 363,40 370,00 +1,51% 1,91% 46.962
09/06/2023 365,20 365,50 359,90 364,50 +0,00% 1,53% 26.754
08/06/2023 366,90 368,30 363,00 364,50 -1,27% 1,44% 38.522
07/06/2023 375,00 375,60 367,10 369,20 -2,02% 2,27% 36.886
06/06/2023 373,70 381,30 372,90 376,80 +0,67% 2,25% 39.435
05/06/2023 368,70 374,40 366,20 374,30 +1,41% 2,22% 44.813
02/06/2023 364,30 370,20 364,10 369,10 +0,93% 1,67% 37.052
01/06/2023 367,40 373,10 359,00 365,70 +0,30% 3,84% 46.067
31/05/2023 368,90 372,20 364,00 364,60 -1,03% 2,22% 365.556
30/05/2023 375,30 376,00 367,30 368,40 -1,86% 2,32% 50.781
29/05/2023 375,00 376,20 373,50 375,40 +0,35% 0,72% 14.965
26/05/2023 372,40 377,00 372,30 374,10 -0,19% 1,26% 33.035
25/05/2023 377,80 379,50 372,20 374,80 -0,66% 1,93% 35.781
24/05/2023 386,60 386,60 375,50 377,30 -2,76% 2,87% 49.032
23/05/2023 385,00 389,00 384,00 388,00 -0,59% 1,30% 35.399
22/05/2023 387,00 392,50 384,60 390,30 +1,06% 2,04% 53.091
19/05/2023 385,00 389,90 382,70 386,20 +0,08% 1,87% 49.023
18/05/2023 383,80 387,00 381,30 385,90 +1,61% 1,49% 53.506
17/05/2023 386,00 392,00 366,60 379,80 +2,48% 6,58% 177.419
16/05/2023 374,60 374,70 355,80 370,60 -1,25% 5,05% 126.401
15/05/2023 370,30 375,40 369,90 375,30 +1,38% 1,49% 39.001
12/05/2023 369,00 371,10 365,70 370,20 +0,52% 1,46% 32.813
11/05/2023 366,00 370,20 363,00 368,30 +1,35% 1,97% 52.561
10/05/2023 364,00 365,60 359,00 363,40 +0,00% 1,81% 36.151
09/05/2023 367,40 367,40 359,30 363,40 -0,36% 2,20% 49.450
08/05/2023 363,40 365,40 357,40 364,70 +0,05% 2,20% 42.494
05/05/2023 361,00 369,80 359,30 364,50 +2,45% 2,91% 81.439
04/05/2023 357,40 358,00 343,50 355,80 +0,23% 4,06% 85.570
03/05/2023 358,30 358,90 353,00 355,00 -1,47% 1,65% 39.663
02/05/2023 355,20 361,20 354,10 360,30 +3,33% 2,00% 44.702